Id-2及MMP-9表达与直肠癌临床病理特征的关系研究

Correlations between expression of Id-2 and MMP-9 and pathological features of rectal cancer

目的分析分化抑制因子2(Id-2)及基质金属蛋白酶-9(MMP-9)表达与直肠癌临床病理特征的关系。方法回顾性分析本院2014年3月至2016年3月收治的98例直肠癌患者的临床资料及其癌组织、癌旁正常组织标本,临床资料完整,所有癌组织标本均经病理确诊。采用免疫组织化学法测定Id-2、MMP-9,记录两者在直肠癌及癌旁正常组织中的表达差异,并探讨Id-2、MMP-9表达的相关性及其与直肠癌病理特征(性别、年龄、肿瘤大小、分化程度、临床分期、淋巴结转移)的关系。结果直肠癌组织中Id-2、MMP-9阳性表达率显著高于癌旁正常组织(P<0.05)。低分化、临床分期为Ⅲ~Ⅳ期、有淋巴结转移的患者Id-2、MMP-9阳性表达率显著高于高及中分化、临床分期为Ⅰ~Ⅱ期、无淋巴结转移的患者(P<0.05)。Spearman相关性分析结果显示,Id-2与MMP-9在结直肠癌中的阳性细胞表达率呈正相关(P<0.05)。结论直肠癌组织中Id-2及MMP-9表达水平较高,在肿瘤发生、发展中有重要意义,且Id-2与MMP-9表达有一定相关性。

Objective To study the correlations between expression of Id-2 and MMP-9 and pathological features of rectal cancer.Methods The clinical data of 98 patients with rectal cancer in our hospital from March 2014 to March 2016 were retrospectively analyzed and collected. All the specimens were confirmed by histological diagnosis. Id-2 and MMP-9 were determined by immunohistochemistry. The expression level of Id-2, MMP-a record 9 in rectal cancer and adjacent normal tissues were recorded and compared.The correlations between expression of Id-2 and MMP-9 and the pathological features of rectal cancer（sex, age, tumor size, differentiation, clinical stage, lymph node metastasis） were explored. Results The level of positive expression of Id-2 and MMP-9 were71.43% and 69.39% in rectal cancer tissues, respectively, and significantly higher than the paracancerous tissues（P 〈 0.05）. The level of positive expression Id-2 and MMP-9 in patients with low differentiation, clinical stage Ⅲ~Ⅳ and lymph node metastasis were significantly higher than patients with high differentiation, clinical stage Ⅰ~Ⅱ stage and no lymph node metastasis（P 〈 0.05）. Spearman correlation analysis showed that the expression of Id-2 was positively correlated with MMP-9 in rectal cancer（P 〈 0.05）. Conclusion Id-2 and MMP-9 highly expressed in rectal cancer and they are closely related to the development of rectal cancer. The expression of Id-2 was positively correlated with MMP-9.